Treatment of Acute Stroke with Recombinant Tissue Plasminogen Activator and Abciximab
Article first published online: 28 JUN 2008
© 2003 Society for Academic Emergency Medicine
Academic Emergency Medicine
Volume 10, Issue 12, pages 1396–1399, December 2003
How to Cite
Morris, D. C., Silver, B., Mitsias, P., Lewandowski, C., Patel, S., Daley, S., Zhang, Z. G. and Lu, M. (2003), Treatment of Acute Stroke with Recombinant Tissue Plasminogen Activator and Abciximab. Academic Emergency Medicine, 10: 1396–1399. doi: 10.1197/S1069-6563(03)00543-8
- Issue published online: 28 JUN 2008
- Article first published online: 28 JUN 2008
- Received March 24, 2003; revision received May 1, 2003; accepted May 5, 2003.
- GP IIb/IIIa
Objectives: Preclinical data suggest that treatment of acute ischemic stroke (AIS) with the combination of recombinant tissue plasminogen activator (rt-PA) and abciximab may increase efficacy and decrease the rate of symptomatic intracranial hemorrhage (sICH). The authors report pilot data of five AIS patients with half-dose rt-PA and abciximab as part of an ongoing phase I safety trial with sICH as the primary outcome. Methods: Five patients with AIS were treated with the combination of half-dose rt-PA (0.45 mg/kg) and abciximab (0.25 mg/kg bolus followed by a 0.125 μg/kg/min infusion over 12 hours). Head computed tomographic scan was obtained after 24 hours of treatment onset. Results: Four patients received the combination of half-dose abciximab and rt-PA without major complications. One patient experienced a parenchymal hematoma type-1 ICH without significant decline of his neurological status. The average National Institutes of Health Stroke Scale change at discharge in comparison with pretreatment was −5.4 ± 7.0, and the median change was 6 points with a range of 4 points (worsening) to −13 points (improvement) (p = 0.07) based on a one-sided t-test. Conclusions: Administration of rt-PA and abciximab to AIS patients was completed without difficulty. No sICH were observed; however, 20% (1 out of 5) experienced an asymptomatic ICH. Based on our observation of five patients, there was a trend of treatment efficacy; however, these results need to be confirmed in a larger-scale placebo-controlled clinical trial.